91 results
8-K
EX-99.1
GRTS
Gritstone Bio Inc
9 May 24
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
4:07pm
in metastatic CRC patients and that our objective of unlocking immunologically ‘cold’ tumors to the benefits of immunotherapy may be within reach,” said
8-K
EX-1.1
GRTS
Gritstone Bio Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:23pm
) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering … such relative benefits but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements
424B5
GRTS
Gritstone Bio Inc
2 Apr 24
Prospectus supplement for primary offering
5:20pm
cytotoxic CD8+ T cell subclass, has the potential to drive transformational therapeutic and prophylactic benefits.
In oncology, we develop vaccines … that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure
424B5
fhd6oegb35jxd63c
1 Apr 24
Prospectus supplement for primary offering
4:43pm
8-K
EX-99.1
f9cpl9q40kth
8 Nov 23
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
4:06pm
8-K
EX-99.1
d1qxv1wzugewmn4lb 30
27 Sep 23
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-10.1
6bwgvc3r8dw2 sx
6 Apr 23
Entry into a Material Definitive Agreement
4:38pm
424B3
03soyqzb
14 Dec 22
Prospectus supplement
5:09pm